<DOC>
	<DOCNO>NCT01984424</DOCNO>
	<brief_summary>The study divide 3 part ( A , B , C ) . Part A double-blind , placebo-controlled , two-period cross-over rechallenge atorvastatin 20 mg. Part B 24-week double-blind , double-dummy comparison evolocumab ezetimibe . Part C 2-year open-label evolocumab extension . The primary hypothesis evolocumab well tolerate result great reduction LDL-C ezetimibe , define mean percent change baseline Weeks 22 24 Part B percent change baseline Week 24 Part B , statin-intolerant hypercholesterolemic subject .</brief_summary>
	<brief_title>Goal Achievement After Utilizing Anti-PCSK9 Antibody Statin Intolerant Subjects-3</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female ≥ 18 ≤ 80 year age Subject LDLC goal History statin intolerance Lipid lower therapy stable prior enrolment least 4 week Fasting triglyceride ≤ 400 mg/dL NYHA III IV heart failure Uncontrolled cardiac arrhythmia Uncontrolled hypertension Type 1 diabetes Poorly control type 2 diabetes Uncontrolled hypothyroidism hyperthyroidism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>High Cholesterol , Treatment high cholesterol , Lowering cholesterol , Lowering high cholesterol , Hypercholesterolemia</keyword>
</DOC>